| Entries |
| Document | Title | Date |
|---|
| 20080227827 | COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS - The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments. | 09-18-2008 |
| 20080242705 | Fluridone as an Anti-Inflammatory Agent - The invention relates to a novel use of fluridone—compound known per se and used as an aquatic erbicide—in the medical field, in particular as an active compound for preparing a medicament having anti-inflammatory activity. Pharmaceutical compositions comprising fluridone as an active compound and pharmaceutically acceptable carriers and/or diluents are also disclosed. Finally, there is disclosed the pro-inflammatory activity of abscisic acid (ABA), a plant hormone which is also found in mammal serum and against which fluridone acts an inhibitor. | 10-02-2008 |
| 20080249136 | Antimicrobial Composition and Method - An antimicrobial composition containing a cationic polymer having limited antimicrobial activity (such as a hydrophobically-modified quaternary ammonium cellulose ether) and an antimicrobial compound (such as one or more compounds selected from the group consisting of diiodomethyl-para-tolylsulfone, ortho-phenylphenol, sodium pyrithione, zinc pyrithione, 3-iodo-2-propynylbutylcarbamate, 2-methyl-4-isothiazolin-3-one, 1,2-benzisothiazolin-3-one, 2-n-octyl-4-isothiazolin-3-one, 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride, 2-(4-thiazolyl)-benzimidazole, β-bromo-β-nitrostyrene, 2,4,4′-trichloro-2-hydroxyphenyl ether, chloroxylenol, chlorocresol, para-tert-amylphenol, N-(4-chlorophenyl)-N′-(3,4 dichlorophenyl)-urea, and para-hydroxybenzoic acid esters). The growth of microorganisms (such as | 10-09-2008 |
| 20080300283 | Microbicidal preparations based on 1, 2-benzisothiazonlin-3-one with a content of aromatic alcohol - The invention relates to microbicidal preparations which comprise a) at least one of 1,2-benzisothiazolin-3-one and its derivatives, b) at least one of 2-mercaptopyridine N-oxide, its salts and derivatives, c) at least one aromatic alcohol and d) at least one alkalinizing agent, or which are prepared by mixing components a) to d), where the preparations have a pH of at least 11. The preparations are characterized by the fact that they are clear and storage-stable, and they are suitable for use as preservatives. | 12-04-2008 |
| 20080312292 | Antipruritics - It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect. | 12-18-2008 |
| 20080319026 | SUBSTITUTED N-ARYL PYRIDINONES - Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 12-25-2008 |
| 20080319027 | Composition and Method for Treating Fibrotic Diseases - The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones have enhanced anti-fibrotic activities than 5-methyl-1-(non-substituted phenyl)-2(1H)-pyridones. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone. Accordingly, there are provided compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat or prevent fibrosis diseases. | 12-25-2008 |
| 20090012128 | MICROBICIDAL AGENT AND MICROBICIDAL COMPOSITION - A microbicidal agent comprising as an effective ingredient at least one selected from the group consisting of p-hydroxybenzaldehyde, 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, 3-hydroxypyridine and vanillin, and a microbicidal composition comprising the microbicidal agent. | 01-08-2009 |
| 20090030047 | PERITONEUM PROTECTING AGENT - It is an objective of the present invention to provide a novel peritoneal membrane protecting agent which can effectively suppress deterioration of peritoneal functions in long-term peritoneal dialysis (PD) patients and the like. The present invention provides a peritoneal membrane protecting agent comprising a pyridoxine or a salt thereof, as an active ingredient. | 01-29-2009 |
| 20090062350 | Pesticidal composition - A pesticidal composition including a microcapsule in which an oil containing a pesticidal active ingredient and an organic solvent is covered with a wall made of a thermosetting resin; at least one kind selected from the group consisting of polyglycerin fatty acid ester, sucrose fatty acid ester and alkylbenzenesulfonic acid or its salt; a thickener, and water is provided. The pesticidal composition has elution performance suited for an applied situation without the need of changing the design of the microcapsule itself As the thermosetting resin, a polyurethane resin or a polyurea resin is preferred. As the pesticidal active ingredient, an insect growth regulating active ingredient such as 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether can be recited. | 03-05-2009 |
| 20090069387 | ANIMAL PARASITE-CONTROL METHOD USING INSECT GROWTH REGULATORS - Methods and formulations for treating animal ectoparasites, effective against parasites such as fleas and ticks are provided. The methods comprise topically co-administering a non-mobile insect growth regulator, a mobile insect growth regulator, and an adulticide to the animal. Parasiticidal formulations for treating animal ectoparasites are also provided, which can be safe to use and avoids the many common deleterious side effects of conventional topical formulations. The topical formulations comprise a combination of two insect growth regulators and an additional insecticide. The topical formulation can be packaged together or packaged so that active components are stored separately prior to administering the topical insecticide formulation to the animal. | 03-12-2009 |
| 20090118339 | LYSINE RELATED DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS - The present invention concerns lysine related derivatives, their use as protease inhibitors, in particular as HIV aspartyl protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present lysine related derivatives with another anti retroviral agent. It further relates to their use in assays as reference compounds or as reagents. | 05-07-2009 |
| 20090131485 | Deuterated pirfenidone - This invention relates to novel substituted pyridinones, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a TNF (tumor necrosis factor)-alpha production inhibitor/TGF (transforming growth factor)-beta inhibitor. | 05-21-2009 |
| 20090163556 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS - The present invention relates to glycinamide derivatives of formula I, | 06-25-2009 |
| 20090170908 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF - The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof | 07-02-2009 |
| 20090258911 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES - The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones have enhanced anti-fibrotic activities than 5-methyl-1-(non-substituted phenyl)-2(1H)-pyridones. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone. Accordingly, there are provided compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat or prevent fibrosis diseases. | 10-15-2009 |
| 20090298889 | PHARMACEUTICAL COMPOSITIONS CONTAINING 2-PYRIDONE DERIVATIVES AS EFFECTIVE COMPONENTS - The present invention herein provides a 2-pyridone derivative which has a cell adhesion-inhibitory activity and which is useful for preventing and/or treating pathema or disease conditions including, for instance, inflammations which relate to leukocytic infiltration. The 2-pyridone derivative is a compound represented by the following general formula (1). In the formula, R | 12-03-2009 |
| 20100035936 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS - The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen compounds of general formula (I), methods for their preparation, and compositions comprising these compounds as well as their use for the treatment or prophylaxis of various disorders in humans or animals. | 02-11-2010 |
| 20100041712 | SUBSTITUTED IMIDAZOLE COMBINATIONS - This invention relates to a composition comprising a combination of a) an alpha substituted 2-benzyl substituted imidazole and b) a 1-N-arylpyrazole, and optionally c) an insect growth regulator, and their use as a parasiticide in mammals. | 02-18-2010 |
| 20100076031 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS - Compounds of the formula (I) are disclosed and are suitable for the treatment of seborrheic dermatitis. | 03-25-2010 |
| 20100099719 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA - The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones having the ability to reduce proteinuria and for treating kidney diseases. The ability to reduce proteinuria has a renoprotective effect for slowing the progression of kidney diseases. A representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone, AKF-PD. Accordingly, the present invention provides compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat proteinuria and kidney diseases. | 04-22-2010 |
| 20100105740 | O-SUBSTITUTED-DIBENZYL UREA-DERIVATIVES AS TRPV1 RECEPTOR ANTAGONISTS - The invention relates to compounds of formula (I) in which R is selected from halogen, alkyl, alkoxy, aryl and heteroaryl; R | 04-29-2010 |
| 20100137375 | Emulsifiable Concentrate - An emulsifiable concentrate (EC) formulation, comprising | 06-03-2010 |
| 20100152250 | CAPSULE FORMULATION OF PIRFENIDONE AND PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS - A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need. | 06-17-2010 |
| 20100160385 | FUNGICIDAL TRIPHENYL-SUBSTITUTED PYRIDONES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, | 06-24-2010 |
| 20100190831 | GPR120 RECEPTOR AGONISTS AND USES THEREOF - GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control. | 07-29-2010 |
| 20100222395 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS - Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine. | 09-02-2010 |
| 20100261764 | SUBSTITUTED 3 -HYDROXYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to novel therapeutic compounds of formula (I) wherein R | 10-14-2010 |
| 20100273834 | TREATMENT OF ONYCHOMYCOSIS AND RELATED COMPOSITIONS INCLUDING UREA - The present invention generally relates to the treatment of onychomycosis. More specifically, it relates to combination therapies for the treatment of onychomycosis and related compositions. In a composition aspect, the present invention provides a composition for the treatment of onychomycosis, wherein the composition includes Ciclopirox and urea. In a method aspect, the present invention provides a method for treating onychomycosis in a patient suffering from the disease. The method involves topically administering a composition to at least one toe or fingernail of the patient and the composition includes Ciclopirox and urea. | 10-28-2010 |
| 20100324097 | Method of Providing Pirfenidone Therapy to a Patient - The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme. | 12-23-2010 |
| 20110003863 | METHOD FOR SYNTHESIZING PIRFENIDONE - A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenzene is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone. | 01-06-2011 |
| 20110003864 | CRYSTALLINE 1-(3-FLUOROPHENYL)-5-METHYL-2-(1H)PYRIDONE, THE PREPARATION METHODS, COMPOSITIONS AND APPLICATIONS THEREOF - Crystalline pyridone compound, which is the white needle crystal containing no water and other crystallization solvents. Its unit cell belongs to monoclinic system and has space group of P2 | 01-06-2011 |
| 20110034519 | NUTRITIONAL SUPPLEMENTS - A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 μg hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof. | 02-10-2011 |
| 20110082176 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases - The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis. | 04-07-2011 |
| 20110086890 | LIQUID PEST CONTROL FORMULATION - The present invention relates to a liquid pest control system that includes a synthetic pyrethroid as a pest control active ingredient and an agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate and tocopherol succinate, and combinations thereof, to reduce or eliminate paraesthesia of the synthetic pyrethroid. The system releases the synthetic pyrethroid efficiently and uniformly. The pest control system is less irritating to the animal's skin as compared to prior art systems, particularly to the small breeds of dogs. The system is useful for making liquid spot-on treatments, sprays and the like. | 04-14-2011 |
| 20110092548 | METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF CEREBRUM AND PHARMACEUTICAL - An object of the present invention is to develop a method of enhancing the cognitive ability of a brain to fundamentally cure a disease. It has been found out that, by using a medicament for treating or preventing a disease including a combination of a major tranquilizer, and vitamin C or a salt thereof and, if necessary, drip infusion, an antidepressant and an iron agent, the cognitive ability of a brain is enhanced, thus, an arbitrary disease including various cancers can be treated. The present invention also provides a method for treating or preventing a disease including a step of administering a major tranquilizer, and vitamin C or a salt thereof to a subject suffering from the disease. | 04-21-2011 |
| 20110092549 | Treatment of Sepsis with 5-Ethyl-1-Phenyl-2(1H)-Pyridone - A pharmaceutical composition comprising 5-ethyl-1-phenyl-2-(1H)-pyridone (5-EPP) and its use for the treatment of sepsis are disclosed. | 04-21-2011 |
| 20110105569 | PHOSPHODIESESTERASE 4 INHIBITORS FOR THE TREATMENT OF A COGNITIVE DEFICIT - The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors. | 05-05-2011 |
| 20110105570 | PHOSPHODIESESTERASE 4 INHIBITORS FOR THE TREATMENT OF A COGNITIVE DEFICIT - The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors. | 05-05-2011 |
| 20110136876 | Altering Pharmacokinetics of Pirfenidone Therapy - The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. | 06-09-2011 |
| 20110144166 | HIGH CONCENTRATION TOPICAL INSECTICIDES CONTAINING PYRETHROIDS - A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth regulator (IGR). The topical insecticide preparation can be packaged together or packaged so that the first and second pyrethroid insecticides are stored separately prior to administration of the insecticide preparation to the animal. The combination of the first and second pyrethroid insecticides with an insect growth regulator results in an insecticide preparation formulated to have enhanced insecticidal activity against fleas and ticks compared to the effectiveness of the first and second insecticides used alone. Further, the combination of the first and second pyrethroid insecticides with an insect growth regulator produces an insecticide preparation having enhanced insecticidal activity against fleas and ticks while advantageously minimizing the total amount of insecticide needed for its effectiveness. | 06-16-2011 |
| 20110166186 | METHODS OF ADMINISTERING PIRFENIDONE THERAPY - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 07-07-2011 |
| 20110172277 | PIRFENIDONE THERAPY AND INDUCERS OF CYTOCHROME P450 - The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. | 07-14-2011 |
| 20110224265 | GEL CONTAINING PIRFENIDONE - The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions | 09-15-2011 |
| 20110263656 | Pirfenidone Treatment for Patients with Atypical Liver Function - Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone. | 10-27-2011 |
| 20110269801 | USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS - Compounds of the formula (I) are disclosed and are suitable for the treatment of seborrheic dermatitis. | 11-03-2011 |
| 20110288133 | HISTONE DEACETYLASE INHIBITORS - This invention relates to novel Histone deacetylases inhibitors. Also disclosed is a method for treating mucositis or cancer with these inhibitors. | 11-24-2011 |
| 20110288134 | COMPOSITION AND METHOD FOR TREATING FIBROSIS - The present invention relates, in general, to fibroproliferative disorders, and, in particular, to a method of treating, preventing or reducing fibroproliferative disorders by administering to a mammal in need a composition comprising pharmacologically effective doses of a cytokine modifier, such as tranilast or pirfenidone, and an anti-oxidant which is a precursor of glutathione, such as N-acetyl-cysteine, or their pharmaceutically acceptable derivatives, salts, metabolites, or structural or functional analogues thereof. | 11-24-2011 |
| 20110301206 | SYNERGISTIC PRESERVATIVE BLENDS - The present invention is a preservative formulation which includes a combination of at least two (2) compounds having bactericidal and/or fungicidal properties wherein the at least two (2) compounds is selected from the group consisting of methylisothiazolinone/piroctone olamine; caprylyl glycol/dehydroacetic acid; undecanol/dehydroacetic acid and lauryl alcohol/sorbic acid. The invention also includes preparations including such combination as well as a method of using the combination to reduce bacterial and fungal load of preparations. | 12-08-2011 |
| 20110313003 | GPR120 RECEPTOR AGONISTS AND USES THEREOF - GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control. | 12-22-2011 |
| 20110313004 | DEUTERATED PYRIDINONES - This invention relates to novel substituted pyridinones, their deuterium-modified derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a TNF (tumor necrosis factor) alpha production inhibitor/TGF (transforming growth factor) beta inhibitor. | 12-22-2011 |
| 20110319453 | Methods of Administering Pirfenidone Therapy - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 12-29-2011 |
| 20120010252 | FUNGICIDAL MIXTURES OF THIOPHENE DERIVATIVE - Disclosed are fungicidal mixtures, compositions and methods for controlling plant diseases relating to combinations comprising (a) N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (including all stereoisomers) or an agriculturally suitable salt thereof; and (b) at least one compound selected from the group consisting of compounds of Formula III or Formula IV which act at the bc | 01-12-2012 |
| 20120015984 | Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients - A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need. | 01-19-2012 |
| 20120015985 | Methods of Administering Pirfenidone Therapy - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 01-19-2012 |
| 20120015986 | SALTS OF DEHYDROACETIC ACID AS A PYRITHIONE STABILIZER IN PLASTICS - The invention provides a method for preventing discoloration of pyrithione-containing materials, in particular plastic materials or other material such as paints, coatings, adhesives or textiles which are exposed to an outdoor environment. The method is likewise suited for preventing discoloration of other pyrithione-containing materials such as personal care compositions like shampoos. A discoloration inhibitor that includes dehydroacetic acid or a salt thereof is added to the pyrithione-containing material. The discoloration is prevented without the addition of a cyclic organic phosphoric acid ester or an organic phosphite. Use of the discoloration inhibitor does not interfere with the antimicrobial effect of the pyrithione. | 01-19-2012 |
| 20120022115 | HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING PROLIFERATIVE DISEASES - Provided herein are hydroxypyridone derivatives, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease. | 01-26-2012 |
| 20120029033 | SPOT-ON PESTICIDE COMPOSITION - A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area. | 02-02-2012 |
| 20120046321 | METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS - The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF). | 02-23-2012 |
| 20120071518 | Treatment of Sepsis with 5-Ethyl-1-Phenyl-2(1H)-Pyridone - A pharmaceutical composition comprising 5-ethyl-1-phenyl-2-(1H)-pyridone (5-EPP) and its use for the treatment of sepsis are disclosed. | 03-22-2012 |
| 20120077850 | PIRFENIDONE TREATMENT FOR PATIENTS WITH ATYPICAL LIVER FUNCTION - Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone. | 03-29-2012 |
| 20120101135 | COMPOSITION CONTAINING SORBITAN MONOCAPRYLATE AND ANTIMICROBIAL SUBSTANCES - The invention relates to liquid compositions which contain a) from 40 to 99.9% by weight of sorbitan monocaprylate and b) from 0.1 to 60% by weight of one or more antimicrobial substances selected from the group consisting of the components b1) to b5): b1) specific organic acids and the salts thereof, b2) specific formaldehyde donors, b3) specific isothiazolinones, b4) specific paraben esters and the salts thereof, and b5) specific pyridones and the salts thereof. The liquid compositions are suitable for the production of cosmetic, dermatological or pharmaceutical products. | 04-26-2012 |
| 20120264788 | ANIMAL PARASITE-CONTROL METHOD USING INSECT GROWTH REGULATORS - Methods and formulations for treating animal ectoparasites, effective against parasites such as fleas and ticks are provided. The methods comprise topically co-administering a non-mobile insect growth regulator and a mobile insect growth regulator to the animal. Parasiticidal formulations for treating animal ectoparasites are also provided, which can be safe to use and avoid the many common deleterious side effects of conventional topical formulations. The topical formulations comprise a combination of two insect growth regulators, a non-mobile insect growth regulator and a mobile insect growth regulator. The topical formulation can be packaged with the two insect growth regulators together or packaged to prevent mixing of the two insect growth regulators prior to administering the topical insecticide formulation to the animal. | 10-18-2012 |
| 20120270908 | SUBSTITUTED 3 -HYDROZYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF - Therapeutic compounds of formula (I) wherein R1 is selected from the group consisting of C | 10-25-2012 |
| 20120277270 | Method for Decreasing Symptoms of Alcohol Consumption - The present invention relates to methods and compositions of metadoxine and physiologically compatible active derivatives thereof, and their use for decreasing symptoms of alcohol consumption as well as in the prevention of alcohol consumption related symptoms in subjects in need thereof. | 11-01-2012 |
| 20120295939 | ANTI-VIRAL AGENT - A method of suppressing the proliferation of virus comprises administering an antiviral agent comprising as an effective component at least one member selected from the group consisting of 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, 3-hydroxypyridine, p-hydroxybenzaldehyde and vanillin to one in need of suppressing of viral proliferation. | 11-22-2012 |
| 20120329834 | COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES - The present invention relates to the use of compounds of general formula (I): (I) for the preparation of medicaments that act against mitochondrial pathologies involving a deficiency in ATP production via the oxidative phosphorylation pathway, such as mitochondrial diseases. | 12-27-2012 |
| 20120329835 | USE OF 1-HYDROXY-2- PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS - Compounds of the formula (1) are disclosed and are suitable for the treatment of seborrheic dermatitis. | 12-27-2012 |
| 20130030024 | Method of Administering Pirfenidone Therapy - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 01-31-2013 |
| 20130045996 | COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS - The invention relates to novel compositions for controlling parasites on animals, comprising an N-arylpyrazole and also a pyrethroid in a formulation comprising aliphatic cyclic carbonates and aliphatic cyclic or acyclic polyethers. | 02-21-2013 |
| 20130045997 | PIRFENIDONE THERAPY AND INDUCERS OF OF CYTOCHROME P450 - The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. | 02-21-2013 |
| 20130072526 | HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING PROLIFERATIVE DISEASES - Provided herein are hydroxypyridone derivatives, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease. | 03-21-2013 |
| 20130131121 | ANTI-VIRAL AGENT - A method of suppressing the proliferation of virus comprises administering an antiviral agent comprising as an effective component at least one member selected from the group consisting of 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, 3-hydroxypyridine, p-hydroxybenzaldehyde and vanillin to one in need of suppressing of viral proliferation. | 05-23-2013 |
| 20130165484 | Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients - A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need. | 06-27-2013 |
| 20130178503 | METHODS OF TREATING HEMATOLOGIC MALIGNANCIES USING 6-CYCLOHEXYL-1-HYDROXY-4-METHYL-2(1H)-PYRIDONE - Provided herein are methods of treating a drug-resistant hematologic malignancy in a subject, which comprises administering to the subject a therapeutically effective amount of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, or a pharmaceutical salt or solvate thereof. | 07-11-2013 |
| 20130225639 | ALTERING PHARMACOKINETICS OF PIRFENIDONE THERAPY - The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. | 08-29-2013 |
| 20130225640 | CYANOACRYLATE-BASED BIO-ADHESIVE COMPOSITION - The present invention relates to a cyanoacrylate-based bio-adhesive composition, and aims to provide a cyanoacrylate-based bio-adhesive composition having an excellent biodegradability and anti-bacterial effect. The present invention provides a cyanoacrylate-based bio-adhesive composition having an enhanced biodegradability by using, as a thickening agent, poly octyl cyanoacrylate generated as a byproduct when preparing octyl cyanoacrylate, and having an excellent anti-bacterial effect by using 3,5-diiodo-4-pyridone-1-acetic acid as an anion stabilizer. | 08-29-2013 |
| 20130245073 | GEL CONTAINING PIRFENIDONE - The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions. | 09-19-2013 |
| 20130289080 | COSMETIC COMPOSITION COMPRISING A FIXING POLYMER AND AN ANTIDANDRUFF AGENT - The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: one or more fixing polymer(s) (i), one or more associative polymer(s) (ii) different from the fixing polymer(s), one or more antidandruff agent(s) (iii), and to a process using this composition, and to the use thereof. | 10-31-2013 |
| 20130303574 | Autodissemination of an Insect-Growth Regulator for Insect Management - The described invention provides a gel formulation of a composition comprising at least one insecticide in an amount effective to control an insect larval population, an apparatus for autodissmenination of an insecticide for insect management containing (1) a cap component, (2) a cup component, and (3) a mesh component, a method and a system for autodissemination for effectively controlling an insect larval population. Also disclosed is an improvided biphasic autodissemination station for control of undesirable insect populations. | 11-14-2013 |
| 20130310424 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. | 11-21-2013 |
| 20130331418 | Methods for Preventing Flea Allergy Dermatitis in Companion Animals - Methods for reducing the incidence of flea allergy dermatitis (FAD) in a companion animal are disclosed, the methods directed to inhibiting blood feeding by ectoparasites on a companion animal. The methods of the present invention involve administering a pesticide composition comprising cyphenothrin to a companion animal, specifically dogs and cats, in doses and proportions which are parasiticidally effective against a variety of ectoparasites, and in formulations which are convenient for topical application to the animal's skin, preferably localized over a small surface area. Such methods are useful in preventing and/or reducing the incidence of flea allergy dermatitis. | 12-12-2013 |
| 20130345264 | SUBSTITUTED N-ARYL PYRIDONES - Disclosed herein are methods of administering deuterated pirfenidone and kits thereof. | 12-26-2013 |
| 20140073673 | Pirfenidone Treatment for Patients with Atypical Liver Function - Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone. | 03-13-2014 |
| 20140107165 | METHOD AND COMPOSITION FOR KILLING PARASITES ON AN ANIMAL - A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area. | 04-17-2014 |
| 20140121246 | GPR120 RECEPTOR AGONISTS AND USES THEREOF - GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control. | 05-01-2014 |
| 20140171471 | HAIR CARE PRODUCTS WITH ANTI-DANDRUFF AGENTS AND CATIONIC PLANT-BASED SURFACTANTS - Compositions for treating keratinic fibers, in particular human hair, that exhibit, in addition to conditioning properties as well as the shine and haptics of keratinic fibers, in particular human hair, impart an improved effect with regard to the removal of dandruff on the keratinic fibers. | 06-19-2014 |
| 20140194475 | ANIMAL PARASITE-CONTROL METHOD USING INSECT GROWTH REGULATORS - Methods and formulations for treating animal ectoparasites, effective against parasites such as fleas and ticks are provided. The methods comprise topically co-administering a non-mobile insect growth regulator and a mobile insect growth regulator to the animal. Parasiticidal formulations for treating animal ectoparasites are also provided, which can be safe to use and avoid the many common deleterious side effects of conventional topical formulations. The topical formulations comprise a combination of two insect growth regulators, a non-mobile insect growth regulator and a mobile insect growth regulator. The topical formulation can be packaged with the two insect growth regulators together or packaged to prevent mixing of the two insect growth regulators prior to administering the topical insecticide formulation to the animal. | 07-10-2014 |
| 20140221434 | ALTERING PHARMACOKINETICS OF PIRFENIDONE THERAPY - The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. | 08-07-2014 |
| 20140235677 | SUBSTITUTED N-ARYL PYRIDINONES - Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 08-21-2014 |
| 20140296300 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING PIRFENIDONE IN SUSTAINED-RELEASE TABLET FORM AND ITS APPLICATION IN THE REGRESSION OF HUMAN CHRONIC RENAL FAILURE, BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS - The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis. | 10-02-2014 |
| 20140323526 | NUTRITIONAL SUPPLEMENTS - A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 .mu.g hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof. | 10-30-2014 |
| 20140350060 | Methods of Administering Pirfenidone Therapy - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 11-27-2014 |
| 20150038537 | Agents For The Control Of Parasites On Animals - The invention relates to agents for the control of parasites on animals, comprising an active substance from the group of the phenylpyrazoles and vitamin E or a derivative thereof, such as particularly vitamin E acetate, as well as optionally a further active substance from the group of the pyrethroids and/or optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such agents for the control of ectoparasites such as, in particular, fleas, ticks and sand flies in pets such as, in particular, in dogs, cats and ferrets. | 02-05-2015 |
| 20150073023 | Method Of Treating Fragile X Syndrome And Related Disorders - The present invention provides methods of alleviating a sign or a symptom of Fragile X Syndrome and relates disorders such as autism spectrum disorders | 03-12-2015 |
| 20150087679 | NUTRITIONAL SLEEP SUPPLEMENT - Embodiments of the present invention relate to a nutritional sleep supplement having a balanced ratio of nutritional elements to facilitate a healthy lifestyle. In one embodiment, a nutritional sleep supplement has a set of active ingredients, the active ingredients comprising: between 50 mg to 600 mg of 5-Hydroxytryptophan; between 125 mg to 1500 mg of calcium lactate; between 50 mg to 600 mg of citric acid; between 125 mg to 1500 mg of gamma-Aminobutyric acid; between 50 mg to 600 mg of L-theanine; between 25 mg to 300 mg of L-tryptophan; between 45 mg to 540 mg of magnesium glycinate; between 1.25 mg to 15 mg of melatonin; between 8.75 mg to 105 mg of niacin; between 7.5 mg to 90 mg of potassium sorbate; and between 10 mg to 100 mg of pyridoxine. | 03-26-2015 |
| 20150126562 | SUBSTITUTED N-ARYL PYRIDONES - Disclosed herein are methods of administering deuterated pirfenidone and kits thereof. | 05-07-2015 |
| 20150141466 | Composition Containing Amino Acid Surfactants, Betaines And N-Methyl-N-Acylglucamines And Having Improved Foam Quality And Higher Viscosity - The invention relates to a composition which contains at least one N-acyl-amino acid surfactant, a betaine surfactant, an N-methyl-N-acylglucamine, said N-methyl-N-acylglucamine having a C | 05-21-2015 |
| 20150148382 | SEMI-SOLID TOPICAL COMPOSITION WHICH CONTAINS PIRFENIDONE AND MODIFIED DIALLYL DISULPHIDE OXIDE (M-DDO) FOR ELIMINATING OR PREVENTING ACNE - The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial/antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical administration known in the state of the art, useful as antifibrotic, anti-inflammatory and antiseptic agent in the prevention, treatment and reversion of acne and post acne lesions. | 05-28-2015 |
| 20150291527 | THIOARYL DERIVATIVES AS GPR120 AGONISTS - The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis. | 10-15-2015 |
| 20150296789 | PESTICIDE COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS - The present invention discloses a pesticide composition comprising a juvenoid, such as pyriproxyfen or hydroprene, and a chitin synthesis inhibitor, such as novaluron. The composition containing the combined actives provides an increased efficacy not exhibited by either active when used alone. | 10-22-2015 |
| 20150313226 | FUNGICIDAL MIXTURES BASED ON PROTHIOCONAZOLE AND A STROBILURIN DERIVATIVE - Disclosed is a fungicidal mixture containing (1) 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thion of formula (I) or the salts or adducts thereof, and at least one additional fungicidal compound or the salts or adducts thereof, selected among picoxystrobin of formula (III) and pyraclostrobin of formula (IV), in a synergistically active quantity. | 11-05-2015 |
| 20150313227 | FUNGICIDAL MIXTURES BASED ON PROTHIOCONAZOLE AND A STROBILURIN DERIVATIVE - Disclosed is a fungicidal mixture containing (1) 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro[1,2,4]-triazole-3-thion of formula (I) or the salts or adducts thereof, and at least one additional fungicidal compound or the salts or adducts thereof, selected among (2) trifloxystrobin of formula (II), (3) picoxystrobin of formula (III), (4) pyraclostrobin of formula (IV), (5) dimoxystrobin of formula (V), and (6) a strobilurin derivative of formula (VI), in a synergistically active quantity. | 11-05-2015 |
| 20150342941 | PIRFENIDONE THERAPY AND INDUCERS OF CYTOCHROME P450 - The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. | 12-03-2015 |
| 20150342942 | METHODS OF TREATING HEMATOLOGIC MALIGNANCIES USING 6-CYCLOHEXYL-1-HYDROXY-4-METHYL-2(1H)-PYRIDONE - Provided herein are methods of treating a drug-resistant hematologic malignancy in a subject, which comprises administering to the subject a therapeutically effective amount of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, or a pharmaceutical salt or solvate thereof. | 12-03-2015 |
| 20150368202 | HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASES - Provided herein are hydroxypyridone derivatives, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods for treating, preventing, or ameliorating one or more symptoms of an inflammatory, neurodegenerative, or immune-mediated disease (e.g., multiple sclerosis). | 12-24-2015 |
| 20160022654 | Methods of Improving Microvascular Integrity - The disclosure relates to methods of preserving or improving microvascular integrity in a patient in need thereof comprising administering pirfenidone therapy to the patient. | 01-28-2016 |
| 20160135460 | FUNGICIDAL COMPOSITION HAVING SYNERGISTIC EFFECT - A fungicidal composition having a synergistic effect is provided. The composition including active ingredients A and B. The active ingredient A is benziothiazolinone, the active ingredient B is one selected from benthiavalicarb-isopropyl, zoxamide, prothioconazole, boscalid, fenamidone, fluopicolide, famoxadone, pyraclostrobin, picoxystrobin or fluazinam, and the weight ratio of the two ingredients is from 1:50 to 50:1. The test results show that the fungicidal composition according to the present invention has an obvious synergistic effect, such that the application rate is reduced and the cost is lowered; and is useful in controlling certain particular fungal diseases on grain crops, vegetables, and fruits with a broadened fungicidal spectrum, a retarded resistance development of the fungi, and an improved control effect. | 05-19-2016 |
| 20160143282 | FUNGICIDAL MIXTURES BASED ON PROTHIOCONAZOLE AND A STROBILURIN DERIVATIVE - Disclosed is a fungicidal mixture containing (1) 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thion of formula (I) or the salts or adducts thereof, and at least one additional fungicidal compound or the salts or adducts thereof, selected among (2) trifloxystrobin of formula (II), (3) picoxystrobin of formula (III), (4) pyraclostrobin of formula (IV), (5) dimoxystrobin of formula (V), and (6) a strobilurin derivative of formula (VI), in a synergistically active quantity. | 05-26-2016 |
| 20160183530 | TOPICAL COMBINATION OF FIPRONIL, PERMETHRIN AND PYRIPROXYFEN - The present invention relates to a liquid topical veterinary pharmaceutical composition consisting of fipronil, permethrin at high concentration and pyriproxyfen such that it does not crystallize when it is applied to the coat of an animal, and to the use thereof in the prevention and/or treatment of infestations of domestic animals by external parasites. The present invention also relates to the use of pyriproxyfen as an inhibitor of the crystallization of a liquid formulation comprising fipronil and permethrin at high concentration. | 06-30-2016 |
| 20160198716 | Method for Producing Emulsifiable Pesticide Solutions | 07-14-2016 |
| 20160250198 | Pirfenidone Treatment for Patients with Atypical Liver Function | 09-01-2016 |
| 20160376231 | ANTIVIRAL COMPOUNDS AND METHODS - The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals. | 12-29-2016 |
